A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901Toshiyuki Harada, Masaharu Nishimura, Satoshi Oizumi et al.|The Oncologist|2013Cited by 14
Evaluation of mandibular invasion by head and neck cancers using99mTc-methylene diphosphonate or99mTc-hydroxymethylene diphosphonate and201Tl chloride dual isotope single photon emission computed tomographyAya Suzuki, Ken Omura, Takashi Togawa et al.|Annals of Nuclear Medicine|2004Cited by 10
Randomized phase II trial of daily administration versus alternate-day administration of S-1 in patients with advanced non-small cell lung cancerAya Suzuki, Toshihiro Nukiwa, Makoto Maemondo et al.|Cancer Treatment and Research Communications|2017Cited by 6
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601)Atsushi Nakamura, Shunichi Sugawara, Hisashi Tanaka et al.|The Oncologist|2020Cited by 6
Semi-quantitative assessment of oral cavity squamous cell carcinoma using201 TI SPECT for evaluating effectiveness of preoperative radiotherapyAya Suzuki, Ken Omura, Toshinao Takenouchi et al.|Annals of Nuclear Medicine|2004Cited by 2